U.S. Transportation Board Sends Union Pacific–Norfolk Southern Merger Back for Revision 
TikTok Expands AI Age-Detection Technology Across Europe Amid Rising Regulatory Pressure 
Lululemon Founder Chip Wilson Escalates Proxy Fight to Remove Advent From Board 
Brazil Supreme Court Orders Asset Freeze of Nelson Tanure Amid Banco Master Investigation 
BHP Posts Record Iron Ore Output as China Pricing Pressures Loom 
U.S. Moves to Expand Chevron License and Control Venezuelan Oil Sales 
Renault Group Global Sales Rise 3.2% in 2025 on Strong International and EV Demand 
Netflix Stock Slips After Earnings as Soft 2026 Guidance Overshadows Subscriber Milestone 
California Attorney General Orders xAI to Halt Illegal Grok Deepfake Imagery 
Syrah Resources and Tesla Extend Deadline on Graphite Supply Dispute to March 
Trump Signs Executive Order to Limit Wall Street Investment in Single-Family Homes 
Boeing Reaches Tentative Labor Deal With SPEEA Workers After Spirit AeroSystems Acquisition 
TSMC Shares Hit Record High as AI Chip Demand Fuels Strong Q4 Earnings 
Anthropic Appoints Former Microsoft Executive Irina Ghose to Lead India Expansion 
Pop Mart Shares Surge in Hong Kong After First Buyback in Nearly Two Years 
NEW YORK, April 26, 2017 -- AXIM® Biotechnologies, Inc. (AXIM® Biotech) (OTC:AXIM), a world leader in cannabinoid research and development, today announced that Lekhram Changoer, Chief Technology Officer of AXIM Biotech, will deliver keynote presentation at the upcoming ExcipientFest 2017, to be held from April 25-26, 2017 at The Rhode Island Convention Center (RICC) in Providence, RI.
Mr. Changoer will present on formulation challenges surrounding the pharmaceutical use of cannabinoids and AXIM's patented extraction and micro-encapsulation technologies, which preserve high THC integrity while enhancing API stability and bioavailability for pharmaceutical preparations.
Keynote presentation: Medical Marijuana: Improving Stability with Novel Delivery Method
Date and Time: 03:30 PM to 04:15 PM ET
Location: 5F RICC
ExcipientFest attracts pharmaceutical scientists from around the world to a two-day forum for the latest scientific developments. ExcipientFest features in-depth technical talks on Excipient Technology, New Drug Applications and Regulatory Issues from industry’s top-pharmaceutical experts. For more information about this conference, please visit: http://www.excipientfest.com.
About AXIM®
AXIM® Biotechnologies, Inc. (OTC:AXIM) focuses on the research, development and production of cannabis-based pharmaceutical, nutraceutical and cosmetic products. Our flagship products include CanChew®, a CBD-based controlled release chewing gum containing 10 mg of industrial hemp-derived CBD, CanChew Plus® (50 mg of CBD) undergoing clinical trials in patients with IBS, MedChew Rx®, a combination CBD/THC gum that is undergoing clinical trials for the treatment of pain and spasticity associated with multiple sclerosis and a number of other pharmaceutical, nutraceutical, cosmetic and consumer products in development. We prioritize the well-being of our customers while embracing a solid fiscal strategy and respect for the environment. For more information, please visit www.AXIMBiotech.com.
FORWARD-LOOKING DISCLAIMER
This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of Axim Biotechnologies, Inc. to be materially different from the statements made herein.
LEGAL DISCLOSURE
AXIM® Biotechnologies does not sell or distribute any products that are in violation of the United States Controlled Substances Act (US.CSA).
Public Relations Contact Andrew Hard Chief Executive Officer CMW Media [email protected] P. +1888 829-0070 www.cmwmedia.com Investor Relations Contact Shiwei Yin, Grayling [email protected] P. +1646 284-9474 Lucia Domville, Grayling [email protected] P. +1646 284-9416 Corporate Contact Info North American Address: 18 East 50th Street, 5 Floor New York, NY 10022 +1 844 294 6246 European Address: Boelewerf 32, Unit 3 2987 VD Ridderkerk, The Netherlands +31 10 8209 227
